Vivek Subbiah: Finding the genomic fusion needles in the haystacks via Liquid Biopsy Precision Medicine

Vivek Subbiah, shared a post by Pashtoon Kasi, Oncologist and Researcher at Weill Cornell Medicine and New York-Presbyterian Hospital, on Twitter, adding the following:

“Finding the genomic fusion needles in the haystacks via Liquid Biopsy Precision Medicine

• 53,842 patients with 66 solid tumor types- Found Rearrangements in FGFR2, BRAF, RET, & ALK
• Delighted to work with phenomenal colleagues in one of the largest datasets & a really cool precision oncology project”

Quoting Pashtoon Kasi’s post:

“Just published Clinical Cancer Research

Is it a myth that you can’t detect fusions on ctDNA?

Presenting one of the largest datasets on Liquid Biopsies & Fusion detection

• 53,842 patients
• 14% had a pathogenic rearrangement detected

Shedding water matters.”

For details click here.
Source: Vivek Subbiah/Twitter and Pashtoon Kasi/Twitter

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.